Abstract
The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.
| Original language | English |
|---|---|
| Pages (from-to) | 25-27 |
| Number of pages | 3 |
| Journal | The Lancet |
| Volume | 337 |
| Issue number | 8732 |
| Publication status | Published - 5 Jan 1991 |
Keywords
- PEPTIDYL-PROLYL ISOMERASE
- RECEIVING FK-506
- DRUG FK-506
- FK506
- TRANSPLANTATION
- RATS
- CYCLOSPORINE
- COMBINATION
- ACTIVATION
- INHIBITION